Nordic Nanovector appoints Dr Lisa Rojkjaer, MD as Chief Medical Officer
Nordic Nanovector ASA (OSE: NANO) is pleased to announce that Lisa Rojkjaer, MD has joined the company today as Chief Medical
Officer (CMO) and as a member of the Executive Management Team. Dr Rojkjaer will lead all clinical development strategy and
execution and support the company’s efforts to identify opportunities to expand its pipeline of innovative targeted therapies for
haematological cancers.
Dr Rojkjaer is a board-certified haematologist with more than 15 years of global and regional clinical development and medical
affairs expertise in the biotech and pharma industries, and has extensive experience in the development of both biologics and small
molecules in haematology and immunology. She joins Nordic Nanovector from Novartis Pharmaceuticals where she held the position of
Global Clinical Program Head, Oncology Global Development. Her previous roles also include CMO at Molecular Partners (Switzerland),
Vice President, Head of Clinical Development at Morphosys AG (Germany), and Head of Global Medical Affairs, Biopharmaceuticals and
Director of Clinical Development, Hematology in the US for Novo Nordisk.
Dr Rojkjaer holds a medical degree from the University of Toronto and received board certification in both internal medicine and
hematology.
Dr Rojkjaer commented: “I am delighted to join Nordic Nanovector at this exciting time in its development. The company’s lead
candidate Betalutin® is demonstrating in clinical studies its potential to become an important new therapy for the treatment of NHL
patients. Its technology is also providing multiple exciting new pipeline opportunities. I look forward to working with the
management team and contributing to the future growth of the company.”
Luigi Costa, Chief Executive Officer, added: “I am very pleased to welcome Lisa to the team. She brings on board strong
expertise in clinical development of novel cancer treatments, particularly in the field of haematology. Lisa’s knowledge and
leadership will be key to the development of Betalutin® as well as to support the growth of Nordic Nanovector’s promising
pipeline.”
About Nordic Nanovector:
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in
haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of
Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin
Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing
market worth over $12 billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab (previously referred to as HH1), conjugated to a low
intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2
study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major
types of NHL with first regulatory submission anticipated in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core
markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC
pipeline to treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
This information is subject to the disclose requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
Nordic Nanovector
IR enquiries:
Luigi Costa, +41 79 124 8601
Chief Executive Officer
or
Tone Kvåle, +47 91 51 95 76
Chief Financial Officer
ir@nordicnanovector.com
or
Media enquiries:
Citigate Dewe Rogerson
Mark Swallow, +44 207 282 2948
or
David Dible, +44 207 282 2949
nordicnanovector@citigatedr.co.uk
View source version on businesswire.com: http://www.businesswire.com/news/home/20161114006727/en/